权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Therapy for Obesity-associated Stress Urinary Incontinence

肥胖相关压力性尿失禁的治疗

基本信息

批准号：
9107289
负责人：
TOM F LUE
金额：
$ 66.73万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-09-01 至 2020-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9107289
关键词：
3-Dimensional Acoustics Adverse effects Affect Anatomy Area Biology Body Weight decreased Cells Clinic Clinical Clustered Regularly Interspaced Short Palindromic Repeats DNA Dyslipidemias Equilibrium Female Follistatin Functional disorder GDF8 gene Gene Expression Profile Genes Growth Inhibitors Hyperglycemia Image Impairment In Situ Insulin Resistance Intervention Laboratories Lead Measures Mediating Mediation Methods MicroRNAs Modeling Molecular Muscle Muscle function Muscle satellite cell Natural regeneration Non-Insulin-Dependent Diabetes Mellitus Obesity Organ Outcome Overweight Pathology Pelvic Floor Muscle Pelvic floor structure Process Rattus Recovery Recruitment Activity Rodent Shock Signal Transduction Site Solvents Sphincter Stem cells Stress Urinary Incontinence Striated Muscles Structure Techniques Therapeutic Therapeutic Effect Tissues Urethra Urethral sphincter base functional outcomes human disease improved muscle regeneration muscular structure novel public health relevance research study satellite cell skeletal muscle wasting stem technological innovation tissue repair

项目摘要

DESCRIPTION (provided by applicant): Overweight females are prone to obesity-associated stress urinary incontinence (OA-SUI), but because the mechanisms underlying its pathology have not been well elucidated, no specific therapies for the condition have been developed. We have identified that dysfunction of urethral and pelvic floor striated muscles contributes to OA-SUI, as atrophy of skeletal muscle often occurs in obese people. Activating endogenous stem/progenitor cells to regenerate damaged muscles could comprise a useful therapeutic approach. However, systemic administration of stem cells or their activators can cause undesirable side effects in off- target organs or tissues. Localized administration of curatives does not resolve this problem, because injected stem or progenitor cells often migrate outside the target area. Our laboratory, which has focused on the biology of endogenous stem/progenitor cells for the past 13 years, is developing a non-invasive method that can recruit and retain these cells at selected sites, or activate them in situ. Our pilot experiments demonstrate that low-energy shock waves (LESW) at a very specific energy level activates urethral and pelvic floor muscle progenitor cells; they also down-regulate the muscle growth inhibitor myostatin. We hypothesize that by activating resident stem cells to grow new myofibers, LESW can reverse OA-SUI. To clarify mechanisms and identify potential clinical approaches, we are also investigating myostatin inhibition via a novel DNA-inhibiting method called "clustered regularly interspaced short palindromic repeats interference" (CRISPRi). We will use a rodent OA-SUI model to assess structural and functional outcomes of treatment with CRISPRi, LESW, or both, and compare the results with the effects of weight-loss (the first line treatment taken in the clinic). To elucidate how obesity affects the structure and function of the female urethral sphincter and pelvic floor muscles, the molecular mechanisms involved in activating its resident stem cells, and the impacts LESW has on their activation and differentiation. We will also establish the feasibility of inducing regeneration of this muscle by inhibiting myostatin signaling. These objectives lead us to propose the following Specific Aims: 1.To examine the effect of LESW and weight loss in a rat model of obesity-associated urethral and pelvic floor striated muscle dysfunction 2.To enhance the recovery of urethral sphincter and pelvic floor muscle by myostatin inhibition in rats with OA-SUI. 3. To identify the effects of dyslipidemia and hyperglycemia on muscle derived stem cells (MDSC) through the modulation of myostatin signaling, and its counteraction by LESW.